Paper TrailKOREA
Why Korean and U.S. stocks moved, checked against filings

Rhythm Pharmaceuticals up 28% on an AstraZeneca bid report. Its 8-K never mentions a deal

Kyndryl rose 30%, Rhythm 28% and Duolingo 26% on Nov. 4. Two moved on earnings that filings confirm; Rhythm moved on a reported $10 billion AstraZeneca offer that the company has not filed anything about.

Rhythm Pharmaceuticals up 28% on an AstraZeneca bid report. Its 8-K never mentions a deal

Basis: Nov. 5, 2026 KST; prices are regular-session closes on Nov. 4 (U.S.)

stock exchange trading

Seoul — U.S. stocks rose on Nov. 4, with the S&P 500 up 1.58% to 7,688.62, the Nasdaq up 1.44% to 25,736.51 and the Russell 2000 small-cap index up 1.58% to 2,856.95. The biggest movers were Kyndryl Holdings, Inc. (KD) at +30.14%, Rhythm Pharmaceuticals, Inc. (RYTM) at +28.04% and Duolingo, Inc. (DUOL) at +25.99%. Kyndryl and Duolingo have earnings releases on file with the SEC, while Rhythm rose on a bid report and its own filings say nothing about a deal.

At a glance

Stock Move (close) Close Dollar volume Why it rose Nature Basis Heat What to check next
Kyndryl (KD) +30.14% $16.84 ~$252M Q2 beat reported; full-year outlook kept Substance, one-off Filing confirms the release only; figures per press reports 0/4 normal Next quarter's results; shrinking revenue
Rhythm (RYTM) +28.04% $110.68 ~$598M Reported $10B AstraZeneca offer Expectation Press reports only; no filing 1/4 caution An official statement or 8-K
Duolingo (DUOL) +25.99% $161.27 ~$1.53B Earnings release, analyst target raises Substance, ongoing Filing confirms the release only; figures per press reports 1/4 caution Next-quarter revenue growth; Nov. 4 Form 144

The jobs report on Nov. 6 and CPI on Nov. 10 are next on the calendar and are a shared risk for all three.

Rhythm Pharmaceuticals rose 28% on a reported AstraZeneca bid (no filing backs it)

Rhythm Pharmaceuticals jumped on a report that AstraZeneca offered about $10 billion for the company. TradingView headlined it as the stock's best day in nearly 16 months on the AstraZeneca $10B bid report, and Yahoo Finance UK carried the same story. The stock closed at $110.68 after falling 7.49% to $86.44 the day before.

The company's filings do not mention a deal. The only filing in the past seven days is an 8-K dated Nov. 3 under Items 2.02 and 9.01, which attaches the third-quarter earnings release and a presentation. Yahoo Finance Singapore also ran a story on a $750 million financing, and Benzinga reported positive UK NICE guidance on the company's drug Imcivree for adults with Bardet-Biedl syndrome. Neither supports the bid report directly.

If accurate, the figure is large: $10 billion is about 30% above the roughly $7.7 billion market value at the close, though that may not reflect any newly issued shares. Volume was 5.3 times the 20-day average and RSI 73.6. The price sits 22.0% above its 20-day average, giving 1 of 4 overheating signals (caution). It is 5.9% below its 52-week high and 14.1% above its 200-day average. Fundamentals pass 2 of 6 checks (passed: debt level, revenue growth of 46.9%; failed: profitability, free cash flow, ROE of 10%, P/E of 25 or less). No filing in the past week is neutral or otherwise.

What decides whether this holds is whether the company or AstraZeneca confirms talks officially, for example in an 8-K. If it stays a press report alone, the gain may unwind. No Form 4 or 144 insider filings appear in the past seven days.

Kyndryl rose 30% after a second-quarter beat

Kyndryl rose 30.14% after reporting fiscal second-quarter 2027 results. Its 8-K (Items 2.02 and 9.01) only attaches the earnings release, and the text carries no revenue or profit figures. GuruFocus reported a beat of estimates with the fiscal 2027 outlook reaffirmed, and a Yahoo call summary said management held its outlook as workforce savings ramp up. The outlook was kept, not raised.

The stock had slid from $15.20 on Oct. 22 to $12.94 on Nov. 3 before jumping to $16.84. Latest data show revenue down 3.3% and a P/E of 45.5. Fundamentals pass 2 of 6 checks (passed: profitability, free cash flow; failed: debt level, ROE of 10%, revenue growth, P/E of 25 or less). Volume was 3.8 times normal, so overheating signals are 0 of 4 (normal), though the price is 24.1% above its 20-day average with RSI at 72.3. It remains 38.8% below its 52-week high. About $252 million traded, roughly 7% of its $3.7 billion market value.

To judge whether it lasts, watch whether cost savings show up as profit next quarter and whether shrinking revenue turns. This is a reaction to one earnings report. No Form 4 or 144 appears in the past seven days.

Duolingo rose 26% after earnings, with a fifth of its market value traded in one day

Duolingo reported earnings after the close on Nov. 3 and rose 25.99% the next day to $161.27. Its 8-K (Items 2.02 and 9.01) attaches the earnings release and a shareholder letter but gives no figures in the text. Headlines from MarketBeat and GuruFocus show Citigroup, JPMorgan, Barclays and Scotiabank raising price targets.

About $1.53 billion traded, roughly 20% of its $7.5 billion market value, and volume was 10 times the 20-day average. It shows 1 of 4 overheating signals (caution), with RSI at 57.6 and the price 14.0% above its 20-day average. It is 38.0% below its 52-week high and 30.3% above its 200-day average. Fundamentals pass all 6 checks, with a P/E of 19.2 and revenue growth of 18.3%. Separately, Kaplan Fox published a notice about a securities class action against the company with a Dec. 7 deadline; no link to today's move is established.

To see whether it holds, watch whether revenue growth stays near 18.3% next quarter, and what the Form 144 (a notice of planned insider selling) filed on Nov. 4 covers; its size is not shown here. A 13G/A ownership update was also filed on Oct. 30.

How earlier picks fared

Close-to-close changes since our earlier articles, by verdict (periods differ by article date):

Verdict Stock (article date) Since
Earnings IDEXX Laboratories (11/3) +4.0%
Earnings Newell Brands (11/3) -1.7%
Earnings Glaukos Corporation (10/30) +1.7%
Earnings Bausch Health Companies Inc. (10/30) -6.4%
Report Nextpower (11/3) +17.1%
Report ADT Inc. (10/30) +0.3%
Report Genmab (10/29) -3.8%
Filing Axogen (10/29) +4.3%

The four earnings stories ranged from -6.4% to +4.0%. Among press-report cases Nextpower added 17.1% while Genmab lost 3.8%, so the same verdict led to different outcomes.

FAQ

Why did Rhythm Pharmaceuticals, Inc. stock go up?

+30.14%. Evidence: ~$252M. What to check next: Q2 beat reported; full-year outlook kept.

Why did Kyndryl Holdings, Inc. stock go up?

+28.04%. Evidence: ~$598M. What to check next: Reported $10B AstraZeneca offer.

Why did Duolingo, Inc. stock go up?

+25.99%. Evidence: ~$1.53B. What to check next: Earnings release, analyst target raises.

← Latest · Daily movers archive